Details of Zymergen's rise and fall emerged in a document filed Friday by Boston-based Gingko Bioworks, which is in the process of acquiring the California biotech in an all-stock deal valued at $300 million.
Details of Zymergen's rise and fall emerged in a document filed Friday by Boston-based Gingko Bioworks, which is in the process of acquiring the California biotech in an all-stock deal valued at $300 million.
About Our Site:
The primary purpose of the site is to provide Real Estate & Mortgage information as it relates to today’s business environment. It can also be used to answer related question you might have about buying, selling, or financing real estate.